Aptorum Group’s Smart Pharma announces launch of its asset backed Smart Pharma token (SMPT), supported by its computational repurposed drug discovery platform Smart-ACT™
SPLP is extremely pleased to have jointly developed the SMPT token with Aenco, an affiliated blockchain development company focused on applications in the healthcare and financial sector. The SMPT token, an ERC-1404 security compliant token, is a unique token that tokenizes valuable pharmaceutical drugs and their underlying intellectual property and associated allocation of cash flows induced by continual product development and commercialization. It is the intention of the Smart Pharma group to continue to incorporate Aenco’s blockchain technology into its pharmaceutical development and commercialization processes.
Relying on intellectual property derived from the Smart-ACT™ platform, Smart Pharma’s in-house new and repurposed drug discovery program, we believe it will revolutionize drug discovery, in particular, drug repurposing and repositioning. Smart-ACT™ stands for Accelerated Commercialization of Therapeutics and encompasses state-of-the-art technology in systematic screening of existing approved drug molecules against selected therapeutic targets. Specifically, the Smart-ACT™ platform comprises a network of modules and processes that simulate the effectiveness of drug molecules against diseases for outcome prediction and selection. The Smart-ACT™ platform, in combination with in vitro and in vivo validation studies, will initially focus on the screening for drugs targeting orphan diseases or unmet medical needs with a target to discover up to 10 new and promising drug candidates per annum.
The SMPT token is created to help foster a community ecosystem of passionate and like-minded people in revolutionising the drug discovery industry who would like to be an integral part of the process. SMPT token is backed by SPLP’s assets, including intellectual property rights of drug candidates created through the Smart-ACT™ program and any royalty monetization income. The SMPT tokens are backed by the following:
- intellectual property rights obtained from drug candidates discovered;
- applicable royalties based on net sales of the licensed products made by Smart Pharma group upon successful commercialization of the drugs;
- a percentage of sublicensing revenue received by Smart Pharma group from third party in regard to the licensed intellectual property rights; and
- a percentage of consideration for assignment of the intellectual property rights to third parties.
SMPT token holder will allow them to benefit from the inherent valuation growth of SPLP’s intellectual property portfolio as well as being entitled to a portion of cash flows both upon any winding-up of SPLP or upon distributions by SPLP (distributions can be made periodically at SPLP’s discretion).
A spokesperson for Smart Pharma commented: “Our Smart-ACT™ platform is a
novel tool that will completely transform the drug repurposing and
discovery industry which traditionally relied on scattered and
serendipitous discoveries, with initial focus on orphan and unmet
diseases and backed by its parent company,
SPLP plans to collaborate with a number of third party exchanges to
establish a secondary market for the SMPT token in Q2 2019 and further
information will be made available on its website and social media
platforms. The SMPT token will not be available for offer or sale to
participants who are residents of
Further information on the Smart-ACT™ platform can be found on our website: http://www.smtph.com.
Further information on the Smart Pharma Token, SMPT, can be found on our website: http://www.smtph.com/token.
Further information on Aenco can be found on the website: http://www.aencoin.com.
About
For more information about
About Smart Pharma
Smart Pharma’s holding company,
For more information about Smart Pharma, please visit www.smtph.com.
Disclaimer and Forward-Looking Statements
This press release includes statements concerning
This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
Investors must rely on their own evaluation of
View source version on businesswire.com: https://www.businesswire.com/news/home/20190424005097/en/
Source:
For Aptorum Group Limited
Investor Relations and Media
Tel:
+852 2117 6611
Email: investor.relations@aptorumgroup.com
Website:
http://www.aptorumgroup.com
For Smart Pharma
Information Request
Tel: +852 2117 6611
Email:
info@smtph.com
Website: http://www.smtph.com